@onclive.bsky.social👀 NXC-201, a sterically optimized BCMA-directed CAR T-cell therapy, produced a high response rates in R/R AL amyloidosis, according to an interim update from the phase 1b/2 NEXICART-2 trial.
Full details 📰: www.onclive.com/view/nxc-201...
@bd-angry.bsky.social#Radiotherapy #Diary Day 33 - brain buzzing complete! #Gratitude to #oncology #nurses
#Celebrate in #Bradford
Diarising 33 days’ radiotherapy, over 7 weeks, to treat my brain #cancer.
@onclive.bsky.social💥 UTRxMYCN M1-14 has been granted dual @fda.gov designations for sarcomas based on preclinical data, moving the treatment closer to helping address unmet needs.
Read more here 📰: onclive.com/view/utrxmyc...
@carlus-2024.bsky.socialOctober 1, 2026
👉 What if a cancer vaccine could be designed for each patient?
🙂 Another encouraging news from Groupe UIG.
Read: lnkd.in/d9RyGiG4
#GroupeUIG #Cancer #Oncology #Immunotherapy #mRNA #PersonalizedMedicine #Biotechnology #Innovation #Health
@uoftpress.bsky.socialWhen common symptoms point to an uncommon diagnosis. A new case report in The Guthrie Clinic Journal of Medicine examines two cases of rare nasal mucosal #melanoma & highlights the importance of early recognition, imaging, and biopsy when symptoms persist. https://bit.ly/GCJM_AAs2 #Oncology
@earthinsider.bsky.socialCan This Engineered Virus Finally Breach Pancreatic Cancer's Toughest Barrier?
Full story 👇
Learn more: https://www.earthinsider.in/2026/10/oncolytic-adenovirus-metastatic.html
#EarthInsider #EarthInsiderNews #EINews #Global #WorldNews #BreakingNews #GlobalAffairs #Oncology #PancreaticCancer
@sinclaircri.bsky.social"By improving the way quality of life outcomes are reported, we can ensure that patient-reported data play a more meaningful role in treatment decisions and future cancer care" by Dr Michael Brundage, co-lead author of the review and former Director of our CCE division. #Oncology #CancerCare #QoL
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVk8mN
@ASCO
#SocialListening #LucidQuest
@biotechstockdaily.bsky.socialFirst patient enrolled in COMPASSION-37, Akeso's global Phase 3 of cadonilimab in first-line HER2-negative gastric cancer. Comparator: chemotherapy with or without nivolumab.
#GastricCancer #Biotech #Oncology
Disclaimer: This is NOT a financial advice
@onclive.bsky.social👀 Looking ahead to the 2026 ESMO Congress? See which breast cancer presentations @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, and Alexis Ann LeVee, MD, are most looking forward to. @myesmo.bsky.social #bcsm #oncology
Sign up to read the full preview ➡️: www.onclive.com/view/breast-...
@onclive.bsky.socialFollowing a pair of CRLs, a third BLA seeking the approval of tabelecleucel for the treatment of EBV+ post-transplant lymphoproliferative disease has been submitted to the @FDA #oncology
Read more: www.onclive.com/view/tabelec...
@onclive.bsky.social🔬 Researchers at @bcmhouston.bsky.social, Texas Children’s Hospital, and Seattle Children’s describe a complete regression of hepatoblastoma in a 3-year-old treated with a novel immunotherapy in the CARE study. #oncology
@onclive.bsky.social📰 The @fda.gov granted fast track designation to plinabulin plus docetaxel for advanced or metastatic nonsquamous NSCLC without actionable genomic alterations after progression on prior therapy. #lcsm #oncology
Full story ➡️: www.onclive.com/view/fda-gra...
@eortc.org📢 Call for Abstracts is OPEN for #EORTCSummit 2027!
Submit your research and share it with the clinical cancer research community.
📅 Abstract submission: 30 September – 4 November 2026
👉 https://event.eortc.org/summit/abstracts/
@currentmedscience.bsky.social#UTROSCTs: rare uterine tumors with uncertain malignant potential. This study combines a literature review and 8 cases revealing novel markers and long term disease free outcomes. #medsky
Full article: doi.org/10.1007/s115...
@carlus-2024.bsky.socialSeptember 30, 2026
👉 A discovery could open a new path to addressing a devastating complication of pancreatic cancer.
🙂 Another encouraging news from Groupe UIG.
Read: doi.org/10.1016/j.ce...
#GroupeUIG #Cancer #PancreaticCancer #Oncology #CellBiology #SingleCell
@oxcerpc.bsky.socialThis will be the first year for Dr Ketan Shah chairing this course, along with @drmarymiller.bsky.social
#Oncology #CPD #HealthcareProfessionals #PalliativeCare #BookNow #Webinar
@dengyuemedicine.bsky.socialKidney cancer progressed after immunotherapy? 🧬
FDA approved belzutifan (Welireg®) + lenvatinib (Lenvima®) on Sept 28 for advanced clear cell RCC after PD-1/PD-L1 therapy: the first HIF-2α inhibitor + VEGFR-TKI combo for these patients.
@healthcaretoday.bsky.socialResearchers at The Royal Marsden NHS Foundation Trust have found that routine whole-body MRI scans can reveal far more about multiple myeloma patient health than simply showing where their cancer is.
@aiinmeditech.bsky.socialOur latest analysis explores how pharma companies can use oncology market sizing, therapy trends, competitive intelligence, and patient insights to identify high-potential markets.
Read more: www.sperresearch.com/Blogs/oncolo...